Resistance looms for KRASG12C inhibitors
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Tumor relapses were commonly observed among patients who initially responded well to K-RasG12C-targeted therapies.
“Tumor relapses were commonly observed among patients who initially responded well to these therapies.6,13,14”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [14]
Preclinical evidence supporting synergy between K-RasG12C and SHP2 inhibition provided the foundation for early-phase clinical trials of combination therapy by Amgen and Mirati Therapeutics in KRASG12C-mutant cancers.
“These compelling preclinical evidences supporting the synergy between K-RasG12C and SHP2 inhibition provided the foundation for early-phase clinical trials of combination therapy by both Amgen and Mirati Therapeutics in KRASG12C-mutant cancers.14”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [14]
Acquired resistance may limit the efficacy of KRAS G12C inhibitors, which suggests that combination therapies may be needed.
“However, the initial enthusiasm has been somewhat tempered by work suggesting that acquired resistance may constrain the inhibitors’ efficacy, which indicates that combination therapies may be needed11–14.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [11]
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · see citing works
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · see citing works
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · see citing works
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · see citing works
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218 · see citing works
Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985 · see citing works
Self-citationSelective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759 · see citing works
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691 · see citing works
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543 · see citing works
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Görgülü, K., Dantes, Z., Wörmann, S. M., Diakopoulos, K. N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0024-8 · Cited by 370 · see citing works
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Mainardi, S., Mulero-Sánchez, A., Prahallad, A., Germano, G., Bosma, A., Krimpenfort, P., Lieftink, C., Steinberg, J. D., de Wit, N., Gonçalves-Ribeiro, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0023-9 · Cited by 320 · see citing works
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
The metabolic landscape of RAS-driven cancers from biology to therapy
Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F. (2021) · Nature Cancer · doi:10.1038/s43018-021-00184-x · Cited by 315 · see citing works
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 192 · see citing works
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164 · see citing works
Glycogen Synthase Kinase 3β in Cancer Biology and Treatment
Domoto, T., Uehara, M., Bolidong, D., & Minamoto, T. (2020) · Cells · doi:10.3390/cells9061388 · Cited by 127 · see citing works
The Importance of Being PI3K in the RAS Signaling Network
Cuesta, C., Arévalo-Alameda, C., & Castellano, E. (2021) · Genes · doi:10.3390/genes12071094 · Cited by 123 · see citing works
Mechanisms of Resistance to KRASG12C Inhibitors
Dunnett-Kane, V., Nicola, P. A., Blackhall, F. H., & Lindsay, C. R. (2021) · Cancers · doi:10.3390/cancers13010151 · Cited by 120 · see citing works
Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
Reita, D., Pabst, L., Pencreach, E., Guérin, É., Dano, L., Rimelen, V., Voegeli, A., Vallat, L. D., Mascaux, C., & Beau‐Faller, M. (2022) · Cancers · doi:10.3390/cancers14051321 · Cited by 101 · see citing works
SP3‐FAIMS Chemoproteomics for High‐Coverage Profiling of the Human Cysteinome**
Yan, T., Desai, H. S., Boatner, L. M., Yen, S. L., Cao, J. X., Palafox, M. F., Jami‐Alahmadi, Y., & Backus, K. M. (2021) · ChemBioChem · doi:10.1002/cbic.202000870 · Cited by 90 · see citing works
Orsburn, B. C., Yuan, Y., & Bumpus, N. N. (2022) · Nature Communications · doi:10.1038/s41467-022-34919-w · Cited by 71 · see citing works
Han, J. H., Kim, Y. K., Kim, H., Lee, J., Oh, M. J., Kim, M., Kim, K. H., Kim, K. H., Yoon, H. J., Lee, M., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12332 · Cited by 71 · see citing works
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population
Schirripa, M., Nappo, F., Cremolini, C., Salvatore, L., Rossini, D., Bensi, M., Businello, G., Pietrantonio, F., Randon, G., Fucà, G., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.04.009 · Cited by 66 · see citing works
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61 · see citing works
Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
Blaquier, J. B., Cardona, A. F., & Recondo, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.787585 · Cited by 60 · see citing works
Resistance looms for KRAS G12C inhibitors and rational tackling strategies
Zhang, J., Zhang, J., Liu, Q., Fan, X., Leung, E. L., Yao, X., & Liu, L. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108050 · Cited by 56 · see citing works
Burns, T. F., Borghaei, H., Ramalingam, S. S., Mok, T. S. K., & Peters, S. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00744 · Cited by 56 · see citing works
Li, L., Wu, Y., Yang, Z., Xu, C., Zhao, H., Liu, J., Chen, J., & Chen, J. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105447 · Cited by 48 · see citing works
Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers
Scharpf, R. B., Balan, A., Ricciuti, B., Fiksel, J., Cherry, C., Wang, C., Lenoue-Newton, M. L., Rizvi, H. A., White, J. R., Baras, A. S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1731 · Cited by 45 · see citing works
Targeting KRAS in PDAC: A New Way to Cure It?
He, Q., Liu, Z., & Wang, J. (2022) · Cancers · doi:10.3390/cancers14204982 · Cited by 36 · see citing works
Structure-based inhibitor design of mutant RAS proteins—a paradigm shift
Nyíri, K., Koppány, G., & Vértessy, B. G. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09914-6 · Cited by 27 · see citing works
Zhou, Y., & Hancock, J. F. (2023) · FEBS Letters · doi:10.1002/1873-3468.14569 · Cited by 27 · see citing works
Li, H., Qi, W.-L., Wang, Y., & Meng, L. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.011 · Cited by 25 · see citing works
Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone
Coley, A. B., Ward, A., Keeton, A. B., Chen, X., Maxuitenko, Y. Y., Prakash, A., Li, F., Foote, J. B., Buchsbaum, D. J., & Piazza, G. A. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.009 · Cited by 23 · see citing works
Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.483 · Cited by 21 · see citing works
Chen, L., Zhang, J., Wang, X., Li, Y., Zhou, L., Lu, X., Dong, G., & Sheng, C. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.009 · Cited by 20 · see citing works
Orsburn, B. C. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00212 · Cited by 18 · see citing works
Bontoux, C., Hofman, V., Brest, P., Ilié, M., Mograbi, B., & Hofman, P. M. (2022) · Cancers · doi:10.3390/cancers14071628 · Cited by 14 · see citing works
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Abdayem, P., & Planchard, D. (2021) · European Respiratory Review · doi:10.1183/16000617.0294-2020 · Cited by 13 · see citing works
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
Ricciuti, B., Mira, A., Andrini, E., Scaparone, P., Michelina, S. V., Pecci, F., Cantini, L., Giglio, A. D., Lamberti, G., Ambrogio, C., et al. (2022) · Drugs in Context · doi:10.7573/dic.2022-7-4 · Cited by 13 · see citing works
Keane, F., Chou, J. F., Walch, H. S., Schoenfeld, J. D., Singhal, A., Cowzer, D., Harrold, E. C., O'Connor, C. A., Park, W., Varghese, A. M., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae095 · Cited by 12 · see citing works
Hofman, P. M. (2021) · Journal of Molecular Pathology · doi:10.3390/jmp2020015 · Cited by 12 · see citing works
AZD4625 is a Potent and Selective Inhibitor of KRASG12C
Chakraborty, A., Hanson, L. L., Robinson, D. M., Lewis, H. J., Bickerton, S., Davies, M., Polański, R., Whiteley, R., Koers, A., Atkinson, J. M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0241 · Cited by 9 · see citing works
Biochemical characterization of the interaction between KRAS and Argonaute 2
Waninger, J. J., Beyett, T. S., Gadkari, V. V., Siebenaler, R. F., Kenum, C., Shankar, S., Ruotolo, B. T., Chinnaiyan, A. M., & Tesmer, J. J. G. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101191 · Cited by 8 · see citing works
Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics
Hamilton, G., & Plangger, A. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1965123 · Cited by 7 · see citing works
TargetingKRAS G12Cmutations in colorectal cancer
Zhao, M., & Wu, A. (2022) · Gastroenterology report · doi:10.1093/gastro/goac083 · Cited by 8 · see citing works
Discoveries in the redox regulation of KRAS
Kramer‐Drauberg, M., & Ambrogio, C. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105901 · Cited by 6 · see citing works
Huang, R., Gong, X., Du, J., Xu, G., Qian, J., Liao, G., Lin, Y., Pan, M., Zheng, B., Yuan, W., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1704347 · Cited by 6 · see citing works
Anti-proteolytic regulation of KRAS by USP9X/NDRG3 in KRAS-driven cancer development
Koo, H., Park, K., Sohn, H., Kang, M.-H., Kim, D. J., Park, Z.-Y., Park, S., Min, S.-H., Park, S.-H., You, Y.-M., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-54476-8 · Cited by 6 · see citing works
Carlisle, J. W., & Harvey, R. D. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320667 · Cited by 4 · see citing works
SP3-FAIMS Chemoproteomics for High Coverage Profiling of the Human CysteinomePreprint
Yan, T., Desai, H., Boatner, L. M., Yen, S., Cao, J., Palafox, M. F., Jami‐Alahmadi, Y., & Backus, K. M. (2020) · ChemRxiv · doi:10.26434/chemrxiv.13487364 · Cited by 4 · see citing works
Shen, H., & Li, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1385761 · Cited by 2 · see citing works
Precision Therapy of Pancreatic Cancer: From Bench to Bedside
Ciecielski, K. J., Berninger, A., & Algül, H. (2020) · Visceral Medicine · doi:10.1159/000509232 · Cited by 2 · see citing works
Lantéri, E., Hofman, V., Bontoux, C., Goffinet, S., Macocco, A., Long-Mira, É., Lassalle, S., Ilié, M., & Hofman, P. M. (2021) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(21)00378-6 · Cited by 2 · see citing works
Abdayem, P., & Planchard, D. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00107-5 · Cited by 1 · see citing works
Bunz, F. (2022) · Springer eBooks · doi:10.1007/978-3-030-99387-0_10 · Cited by 1 · see citing works
Autres cibles addictives (KRAS, RET, HER2, NTRK…)
Simon, E., Abdayem, P., Planchard, D., & Greillier, L. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00120-3 · Cited by 1 · see citing works
Recent Developments, Challenges and Opportunities in Targeting the KRAS Pathway
Pothuganti, M. K., Mitra, S., Iyer, P. S., & Gowda, N. M. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220704104028
Data from Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers
Scharpf, R. B., Balan, A., Ricciuti, B., Fiksel, J., Cherry, C., Wang, C., Lenoue-Newton, M. L., Rizvi, H. A., White, J. R., Baras, A. S., et al. (2023) · doi:10.1158/0008-5472.c.6514292.v1
Autres cibles addictives (KRAS, RET, HER2, NTRK…)
Planchard, D., Simon, É., Abdayem, P., & Greillier, L. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00140-4
Autres cibles addictives (KRAS, RET, HER2, NTRK...)
Cortot, A. B., Abdayem, P., & Planchard, D. (2024) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(24)00090-9
What Are the Practical Applications of Single-Cell Proteomics?
Orsburn, B. C. (2026) · Proteomes · doi:10.3390/proteomes14020026
Survivin Promotes the Formation of a Microtubule-Based Glycolytic HubPreprint
Neumann, J., Chang, W.-H., Ackermann, S. E., Zanotelli, M. R., Markovich, T., 杨闰英, Lefkowitz, J. R., Enomoto, S., Le, H. H., Lee, M.-T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.28.747899
- Authors
- Hata, A. N., & Shaw, A. T.
- Affiliations
- Harvard University (US)
- Corresponding author
- Hata, Aaron N.
- Shaw, Alice T.
- Venue
- Nature Medicine
- Published
- 2020-02
- Volume
- 26
- Issue
- 2
- Pages
- 169-170
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W3004610133
- Cited by
- 51
- References
- 12
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 3 · 2023: 4 · 2022: 15 · 2021: 16 · 2020: 9
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS G12C inhibitors, drug resistance, KRAS, resistance mechanisms, bypass signaling, inhibitor binding, cancer therapy
- MeSH terms
- Antineoplastic Agents, Humans, Lung Neoplasms, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
